Journal articles: 'Survival outcomes'

1

Rothstein, Jules M. "Outcomes and Survival." Physical Therapy 76, no. 2 (February 1, 1996): 126–27. http://dx.doi.org/10.1093/ptj/76.2.126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Buyze, Jozefien, and Els Goetghebeur. "Crossover studies with survival outcomes." Statistical Methods in Medical Research 22, no. 6 (June 29, 2011): 612–29. http://dx.doi.org/10.1177/0962280211402258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Steingrimsson, Jon Arni, and Samantha Morrison. "Deep learning for survival outcomes." Statistics in Medicine 39, no. 17 (April 13, 2020): 2339–49. http://dx.doi.org/10.1002/sim.8542.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kim, Michelle M., Bouthaina S. Dabaja, Jeffrey Medeiros, Stella Kim, Pamela Allen, Patricia Chevez-Barrios, Dan S. Gombos, and Nathan Fowler. "Survival Outcomes of Primary Intraocular Lymphoma." American Journal of Clinical Oncology 39, no. 2 (April 2016): 109–13. http://dx.doi.org/10.1097/coc.0000000000000028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Vallejos, Catalina A., and Mark F. J. Steel. "Bayesian survival modelling of university outcomes." Journal of the Royal Statistical Society: Series A (Statistics in Society) 180, no. 2 (July 14, 2016): 613–31. http://dx.doi.org/10.1111/rssa.12211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Omer, N., K. Boucher, and J. DiSario. "SURVIVAL OUTCOMES IN FAMILIAL PANCREATIC CANCER." Pancreas 29, no. 4 (November 2004): 348. http://dx.doi.org/10.1097/00006676-200411000-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zhang, Eva, Emily Granger, Monique Malouf, and Allan R. Glanville. "Survival Outcomes of Redo Lung Transplantation." Heart, Lung and Circulation 23, no. 1 (January 2014): e63. http://dx.doi.org/10.1016/j.hlc.2013.10.079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Megwalu, Uchechukwu C., and Andrew G. Sikora. "Survival Outcomes in Advanced Laryngeal Cancer." JAMA Otolaryngology–Head & Neck Surgery 140, no. 9 (September 1, 2014): 855. http://dx.doi.org/10.1001/jamaoto.2014.1671.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kashkouli, Mohsen Bahmani, Parya Abdolalizadeh, Mitra Oghazian, Yasaman Hadi, Nasser Karimi, and Mahya Ghazizadeh. "Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis." British Journal of Ophthalmology 103, no. 10 (December 4, 2018): 1460–65. http://dx.doi.org/10.1136/bjophthalmol-2018-312688.

Full text

Abstract:

AimTo report the frequency and factors affecting patients’, globe and vision survivals in rhino-orbito-cerebral mucormycosis (ROCM).MethodsThis is a retrospective study of 63 patients (79 eyes) with biopsy-proven ROCM at a university hospital 2008–2016. Systemic and ophthalmic manifestations, imaging, management and final outcomes were recorded. Globe survival was defined as no exenteration and vision survival as final visual acuity of light perception and more.ResultsMean age was 55.5 (SD 12.9) years with no gender preference. Diabetes was the most common underlying disease (68.3%). Patient survival was observed in 57.1 % (36/63). Presence of frozen eye (OR 4.6), nasal mucosal involvement (OR 7.3) and shorter duration of antifungal therapy (OR 1.03) were significantly associated with lower patient survival. Exenteration did not significantly change the survival. Globe survival was detected in 43% (34/79). Higher white blood cell (WBC) count was associated with a lower globe survival (p=0.02). Vision survival was observed in 25.3% (20/79) in whom younger age was significantly associated with a worse vision survival.ConclusionPatient, globe and vision survivals were 57%, 43% and 25%, respectively. Exenteration did not affect the patients’ survival. While frozen eye and nasal mucosal involvement were significantly associated with a lower survival, higher WBC count significantly increased the risk of exenteration.

APA, Harvard, Vancouver, ISO, and other styles

10

Sjölander, Arvid, and Stijn Vansteelandt. "Doubly robust estimation of attributable fractions in survival analysis." Statistical Methods in Medical Research 26, no. 2 (December 16, 2014): 948–69. http://dx.doi.org/10.1177/0962280214564003.

Full text

Abstract:

The attributable fraction is a commonly used measure that quantifies the public health impact of an exposure on an outcome. It was originally defined for binary outcomes, but an extension has recently been proposed for right-censored survival time outcomes; the so-called attributable fraction function. A maximum likelihood estimator of the attributable fraction function has been developed, which requires a model for the outcome. In this paper, we derive a doubly robust estimator of the attributable fraction function. This estimator requires one model for the outcome, and one joint model for the exposure and censoring. The estimator is consistent if either model is correct, not necessarily both.

APA, Harvard, Vancouver, ISO, and other styles

11

Shaib, Walid L., Katerina Zakka, Weixing Huang, Zhengjia Chen, Olatunji B. Alese, Christina Wu, Mehmet Akce, and Bassel F. El-Rayes. "Survival Outcomes of Acinar Cell Pancreatic Cancer." Pancreas 50, no. 4 (April 2021): 529–36. http://dx.doi.org/10.1097/mpa.0000000000001788.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Brown, Nicholas F., Diego Ottaviani, John Tazare, John Gregson, Neil Kitchen, Sebastian Brandner, Naomi Fersht, and Paul Mulholland. "Survival Outcomes and Prognostic Factors in Glioblastoma." Cancers 14, no. 13 (June 28, 2022): 3161. http://dx.doi.org/10.3390/cancers14133161.

Full text

Abstract:

Background: IDH-wildtype glioblastoma is the most common malignant primary brain tumour in adults. As there is limited information on prognostic factors outside of clinical trials; thus, we conducted a retrospective study to characterise the glioblastoma population at our centre. Methods: Demographic, tumour molecular profiles, treatment, and survival data were collated for patients diagnosed with glioblastoma at our centre between July 2011 and December 2015. We used multivariate proportional hazard model associations with survival. Results: 490 patients were included; 60% had debulking surgery and 40% biopsy only. Subsequently, 56% had standard chemoradiotherapy, 25% had non-standard chemo/radio-therapy, and 19% had no further treatment. Overall survival was 9.2 months. In the multivariate analysis, longer survival was associated with debulking surgery vs. biopsy alone (14.9 vs. 8 months) (HR 0.54 [95% CI 0.41–0.70]), subsequent treatment after diagnosis (HR 0.12 [0.08–0.16]) (standard chemoradiotherapy [16.9 months] vs. non-standard regimens [9.2 months] vs. none [2.0 months]), tumour MGMT promotor methylation (HR 0.71 [0.58–0.87]), and younger age (hazard ratio vs. age < 50: 1.70 [1.26–2.30] for ages 50–59; 3.53 [2.65–4.70] for ages 60–69; 4.82 [3.54–6.56] for ages 70+). Conclusions: The median survival for patients with glioblastoma is less than a year. Younger age, debulking surgery, treatment with chemoradiotherapy, and MGMT promotor methylation are independently associated with longer survival.

APA, Harvard, Vancouver, ISO, and other styles

13

Wiley, Frieda. "Cabazitaxel Yields Survival Outcomes Similar to Paclitaxel." Oncology Times 43, S15 (August 5, 2021): 30. http://dx.doi.org/10.1097/01.cot.0000771956.91679.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Nayan, Madhur, Nahid Punjani, David N. Juurlink, Antonio Finelli, Peter C. Austin, Girish S. Kulkarni, Elizabeth Uleryk, and Robert J. Hamilton. "Metformin Use and Kidney Cancer Survival Outcomes." American Journal of Clinical Oncology 42, no. 3 (March 2019): 275–84. http://dx.doi.org/10.1097/coc.0000000000000512.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Al-Juhaishi, Taha, Laura Alder, and Asit K. Paul. "Survival outcomes in sarcomatoid renal cell carcinoma." Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018): e16559-e16559. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Maheshwari, V., J. Falk, D. Landsittel, T. Seenivasan, R. Johnson, H. Edington, E. Avissar, and V. Vogel. "Survival outcomes of breast cancer in pregnancy." Journal of Clinical Oncology 22, no. 14_suppl (July 15, 2004): 854. http://dx.doi.org/10.1200/jco.2004.22.90140.854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hack, Maureen. "Survival and Neurodevelopmental Outcomes of Preterm Infants." Journal of Pediatric Gastroenterology and Nutrition 45, Suppl 3 (December 2007): S141—S142. http://dx.doi.org/10.1097/01.mpg.0000302959.55428.05.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Knight, Lynda J., Julia M. Gabhart, Karla S. Earnest, Kit M. Leong, Andrew Anglemyer, and Deborah Franzon. "Improving Code Team Performance and Survival Outcomes." Critical Care Medicine 42, no. 2 (February 2014): 243–51. http://dx.doi.org/10.1097/ccm.0b013e3182a6439d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Maheshwari, V., J. Falk, D. Landsittel, T. Seenivasan, R. Johnson, H. Edington, E. Avissar, and V. Vogel. "Survival outcomes of breast cancer in pregnancy." Journal of Clinical Oncology 22, no. 14_suppl (July 15, 2004): 854. http://dx.doi.org/10.1200/jco.2004.22.14_suppl.854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Younge, Noelle, Ricki F. Goldstein, Carla M. Bann, Susan R. Hintz, Ravi M. Patel, P. Brian Smith, Edward F. Bell, et al. "Survival and Neurodevelopmental Outcomes among Periviable Infants." New England Journal of Medicine 376, no. 7 (February 16, 2017): 617–28. http://dx.doi.org/10.1056/nejmoa1605566.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Lynch, Siobhan P., Xiudong Lei, Mariana Chavez-Mac Gregor, Limin Hsu, Funda Meric-Bernstam, Thomas A. Buchholz, Hong Zhang, Gabriel N. Hortobagyi, Vicente Valero, and Ana M. Gonzalez-Angulo. "Breast cancer multifocality-multicentricity and survival outcomes." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 1104. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1104.

Full text

Abstract:

1104 Background: Studies have consistently shown a correlation between multifocal (MF) and multicentric (MC) breast cancers and the rate and extent of lymph node metastases, but the literature is divided on whether there is a corresponding impact on survival outcomes. In the absence of compelling evidence to dictate otherwise, the convention according to current TNM staging guidelines has been to stage and treat MF and MC cancers according to the diameter of the largest lesions, without taking other foci of disease into consideration. We evaluated a large single institution cohort of MF and MC breast cancers to determine their frequency, clinico-pathological characteristics and effect on survival outcomes. Methods: MF and MC were defined pathologically as more than one lesion in the same quadrant and more than one lesion in separate quadrants, respectively. Patients were categorized by presence or absence of MF or MC disease. Kaplan-Meier product limit method was used to calculate relapse-free survival (RFS), breast cancer-specific survival (BCSS) and overall survival (OS). Cox proportional hazards models were fit to determine independent associations of MF/MC disease with survival outcomes. Results: Out of 3924 patients, 942 (24%) had MF (n=695) or MC (n=247) disease. MF and MC disease was associated with higher T-stages (T2 26% vs. 21.6%; T3 7.4% vs. 2.3%, P<0.001), higher nuclear grade (grade 3 44% vs. 38.2%, P<0.001), lymphovascular invasion (26.2% vs. 19.3%, P<0.001) and lymph node metastases (43.1% vs. 27.3%, P<0.001). After a median follow up of 51 months, MC but not MF breast cancers were associated with significantly worse 5-year RFS (90% vs. 95%, P=0.02) and BCSS (95% vs. 97%, P=0.01), and a trend towards worse 5-year OS (92% vs. 93%, P=0.08). After controlling for other risk factors, multifocality and multicentricity did not have an independent impact on RFS, BCSS or OS. This was true for the subset of T1N0 breast cancers as well. Conclusions: MF and MC breast cancers occurred in 24% of the cases and were associated with poor prognostic factors, but they were not independent predictors of worse survival outcomes. Our findings support the current TNM staging system of using the diameter of the largest lesion to assign T-stage.

APA, Harvard, Vancouver, ISO, and other styles

22

Le Du, Fanny, Takeo Fujii, Minjeong Park, Diane Liu, Limin Hsu, Ana M. Gonzalez-Angulo, and Naoto T. Ueno. "Impact of clinical trial on survival outcomes." Breast Cancer Research and Treatment 159, no. 2 (August 16, 2016): 273–81. http://dx.doi.org/10.1007/s10549-016-3942-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kehoe, Sean. "Olaparib and ovarian cancer—overall survival outcomes." Lancet Oncology 17, no. 11 (November 2016): 1474–75. http://dx.doi.org/10.1016/s1470-2045(16)30433-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Al-Marhoon, Mohammed S., Ahmed Mosbah Osman, Mohammed M. Kamal, and Ahmed A. Shokeir. "Incidental vs symptomatic renal tumours: Survival outcomes." Arab Journal of Urology 9, no. 1 (March 2011): 17–21. http://dx.doi.org/10.1016/j.aju.2011.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Tsang, D. S. C., L. Khan, J. Perry, H. Soliman, A. Sahgal, J. Keith, T. Mainprize, S. Das, L. Zhang, and M. Tsao. "Survival Outcomes in Elderly Patients With Glioblastoma." International Journal of Radiation Oncology*Biology*Physics 93, no. 3 (November 2015): E55—E56. http://dx.doi.org/10.1016/j.ijrobp.2015.07.683.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sunil, Bhanu Jayanand, Ravisankar Palaniappan, Balasubramanian Venkitaraman, and Rama Ranganathan. "Surgical Resection for Hepatoblastoma—Updated Survival Outcomes." Journal of Gastrointestinal Cancer 49, no. 4 (September 30, 2017): 493–96. http://dx.doi.org/10.1007/s12029-017-0005-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Moore, T., S. Johnson, E. Hennessy, P. Chisholm, and N. Marlow. "The epicure studies: better survival, better outcomes?" Archives of Disease in Childhood - Fetal and Neonatal Edition 96, Supplement 1 (June 1, 2011): Fa16. http://dx.doi.org/10.1136/adc.2011.300160.49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Younge, Noelle, Ricki F. Goldstein, Carla M. Bann, Susan R. Hintz, Ravi M. Patel, P. Brian Smith, Edward F. Bell, et al. "Survival and Neurodevelopmental Outcomes Among Periviable Infants." Obstetrical & Gynecological Survey 72, no. 7 (July 2017): 401–3. http://dx.doi.org/10.1097/ogx.0000000000000453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Sidaway, Peter. "CpG island methylation indicates inferior survival outcomes." Nature Reviews Clinical Oncology 13, no. 8 (July 5, 2016): 465. http://dx.doi.org/10.1038/nrclinonc.2016.107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Pires, Magda C., Enrico A. Colosimo, and Arlaine A. Silva. "Survival Weibull regression model for mismeasured outcomes." Communications in Statistics - Theory and Methods 47, no. 3 (September 14, 2017): 601–14. http://dx.doi.org/10.1080/03610926.2017.1309434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Shockley, Ross, Benjamin Johnston, James L. Netterville, and Sarah L. Rohde. "Survival and Functional Outcomes following Total Glossectomy." Otolaryngology–Head and Neck Surgery 149, no. 2_suppl (August 23, 2013): P197. http://dx.doi.org/10.1177/0194599813496044a166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Facciorusso, Antonio, Jose Ferrusquía, and Nicola Muscatiello. "Lead time bias in estimating survival outcomes." Gut 65, no. 3 (July 10, 2015): 538–39. http://dx.doi.org/10.1136/gutjnl-2015-310199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Tashiro, J., J. Sola, O. Ekwenna, A. Tekin, and E. Perez. "Pediatric Liver Transplantation: Survival Outcomes, 1997-2009." Transplantation 98 (July 2014): 169. http://dx.doi.org/10.1097/00007890-201407151-00515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Younge, N., R. F. Goldstein, C. M. Bann, S. R. Hintz, R. M. Patel, P. B. Smith, E. F. Bell, et al. "Survival and Neurodevelopmental Outcomes Among Periviable Infants." Obstetric Anesthesia Digest 37, no. 3 (September 2017): 149–50. http://dx.doi.org/10.1097/01.aoa.0000521247.86996.2d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Cheung, Li C., Qing Pan, Noorie Hyun, and Hormuzd A. Katki. "Prioritized concordance index for hierarchical survival outcomes." Statistics in Medicine 38, no. 15 (April 7, 2019): 2868–82. http://dx.doi.org/10.1002/sim.8157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Tsuboi, Norihiko, Kentaro Ide, Nao Nishimura, Satoshi Nakagawa, and Noriko Morimoto. "Pediatric tracheostomy: Survival and long-term outcomes." International Journal of Pediatric Otorhinolaryngology 89 (October 2016): 81–85. http://dx.doi.org/10.1016/j.ijporl.2016.07.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Tsang, D. S., L. Khan, J. R. Perry, H. Soliman, A. Sahgal, J. L. Keith, T. G. Mainprize, S. Das, L. Zhang, and M. N. Tsao. "Survival Outcomes in Elderly Patients with Glioblastoma." Clinical Oncology 27, no. 3 (March 2015): 176–83. http://dx.doi.org/10.1016/j.clon.2014.11.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Liu, Yan, Xiao-Gang Kang, Qiong Gao, Yu Liu, Chang-Geng Song, Xiao-Jing Shi, Jia-Ning Wu, and Wen Jiang. "Long-Term Outcomes among Patients with Prolonged Disorders of Consciousness." Brain Sciences 13, no. 2 (January 23, 2023): 194. http://dx.doi.org/10.3390/brainsci13020194.

Full text

Abstract:

Purpose: To evaluate the long-term survival and functional outcomes of patients with prolonged disorders of consciousness (pDoC) 1–8 years after brain injuries. Methods: Retrospective study to assess the long-term survival and functional outcomes of patients with pDoC was conducted. We performed Cox regression and multivariate logistic regression to calculate hazard ratios (HRs) for the outcome of survival and to identify risk factors of the functional outcome. Results: We recruited 154 patients with pDoC. The duration of follow-up from disease onset was 1–8 years. The median age was 46 years (IQR, 32–59), and 65.6% (n = 101) of them were men. During the follow-up period, one hundred and ten patients (71.4%) survived; among them, 52 patients had a good outcome. From the overall survival curve, the 1-, 3-, and 8-year survival rates of patients were about 80.5%, 72.0%, and 69.7%, respectively. Cox regression analysis revealed a significant association between the lower APACHE II score (p = 0.005) (cut-off score ≥ 18) and the presence of sleep spindles (p = 0.001) with survival. Logistic regression analysis demonstrated a higher CRS-R score (cut-off score ≥ 7), and presence of sleep spindles were related to a favorable outcome among patients with pDoC. Conclusions: Sleep spindles are correlated with both long-term survival and long-term functional outcome in pDoC patients.

APA, Harvard, Vancouver, ISO, and other styles

39

Kousoulas, Lampros, Nikos Emmanouilidis, Wilfried Gwinner, Jürgen Klempnauer, and Frank Lehner. "High-Urgency Renal Transplantation: Indications and Long-Term Outcomes." Journal of Transplantation 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/314239.

Full text

Abstract:

The concept of high-urgency (HU) renal transplantation was introduced in order to offer to patients, who are not able to undergo long-term dialysis treatment, a suitable renal graft in a short period of time, overcoming by this way the obstacle of the prolonged time spent on the waiting list. The goal of this study was to evaluate the patient and graft survivals after HU renal transplantation and compare them to the long-term outcomes of the non-high-urgency renal transplant recipients. The clinical course of 33 HU renal transplant recipients operated on at our center between 1995 and 2010 was retrospectively analyzed. The major indication for the HU renal transplantation was the imminent lack of access for either hemodialysis or peritoneal dialysis (67%). The patient survival of the study population was 67%, 56%, and 56%, whereas the graft survival was 47%, 35% and 35%, at 5, 10, and 15 years, respectively. In the comparison between our study population and the non-HU renal transplant recipients, our study population presented statistically significant(P<0.05)lower patient survival rates. The HU renal transplant recipients also presented lower graft survival rates, but statistical significance(P<0.05)was reached only in the 5-year graft survival rate.

APA, Harvard, Vancouver, ISO, and other styles

40

Naseripour, M., H. Nazari, P. Bakhtiari, M. Modarres-zadeh, P. Vosough, and M. Ausari. "Retinoblastoma in Iran: outcomes in terms of patients' survival and globe survival." British Journal of Ophthalmology 93, no. 1 (October 24, 2008): 28–32. http://dx.doi.org/10.1136/bjo.2008.139410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Li, Jialiang, Qi Zheng, Limin Peng, and Zhipeng Huang. "Survival impact index and ultrahigh‐dimensional model‐free screening with survival outcomes." Biometrics 72, no. 4 (February 22, 2016): 1145–54. http://dx.doi.org/10.1111/biom.12499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lotan, Yair, Jeffrey A. Cadeddu, J. Jack Lee, Claus G. Roehrborn, and Scott M. Lippman. "Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes." Journal of Clinical Oncology 23, no. 9 (March 20, 2005): 1911–20. http://dx.doi.org/10.1200/jco.2005.03.137.

Full text

Abstract:

Purpose To assess the estimated effect of finasteride prevention of prostate cancer on overall survival. Methods Data for our decision tree model came from men in the two arms (finasteride or placebo) of the Prostate Cancer Prevention Trial (PCPT) and from clinically localized prostate cancer patients studied for long-term survival outcomes. Our model compared survival outcomes for men treated with finasteride or placebo. Prostate cancer rates were based on the 7-year period prevalence of prostate cancer detected in the PCPT; survival probabilities were abstracted from the long-term outcome studies. We assessed variability in the PCPT and long-term survival studies to test the variability of our model. Results Survival advantages for a finasteride-treated (v those not treated with finasteride) population include gains of 1.7 months in 15-year cause-specific survival (assuming finasteride-altered Gleason scores and prostate cancer prevalence rates in the PCPT), of up to 3 months for cancers treated conservatively or surgically (assuming finasteride does not alter Gleason scores), and of 0.35 months (assuming the rate of cancers detected by for-cause biopsies in the PCPT), which increased to 1.7 months when assuming a 30% rate of biopsy-detected cancer in the PCPT placebo group. Model-variability analyses support several survival benefits associated with finasteride (eg, the uniform benefits assuming finasteride does not alter Gleason scores) but question certain others (eg, in 15-year recurrence-free survivals assuming finasteride does alter Gleason scores). Conclusion Finasteride can impart survival benefits according to our model, especially when we assume that finasteride does not alter Gleason scores.

APA, Harvard, Vancouver, ISO, and other styles

43

Park, Gihun, Chiwon Ahn, and Jae Hwan Kim. "Nationwide population-based study of poisoning-induced out-of-hospital cardiac arrest in South Korea." BMJ Open 12, no. 4 (April 2022): e060378. http://dx.doi.org/10.1136/bmjopen-2021-060378.

Full text

Abstract:

ObjectiveTo evaluate the characteristics of poisoning-induced out-of-hospital cardiac arrest (pOHCA) and the factors influencing survival to discharge and good neurological outcomes using a nationwide, population-based database.DesignNationwide, retrospective, population-based cohort study.Setting and participantsThis study included adult patients who had experienced pOHCA and those who had not (non-pOHCA patients) in South Korea from January 2008 to December 2018.Outcome measuresThe primary outcome was survival to discharge, and the secondary outcome was a good neurological outcome.MethodsThe basic characteristics of pOHCA and non-pOHCA patients were analysed by descriptive analysis. Logistic regression analysis was conducted for related variables, including pOHCA.ResultsA total of 173 190 patients were included, and 3582 patients (2.1%) were in the pOHCA group. Some of the pOHCA patients were young (58.2±17.8 vs 69.0±15.5, p<0.001), a few of their cardiac arrests were witnessed (12.8% vs 45.1%, p<0.001), a few were resuscitated by bystanders (8.2% vs 14.8%, p<0.001) and they had low shockable rhythm rates (1.2% vs 8.8%, p<0.001). They showed significantly lower survival to discharge and poorer neurological outcomes than non-pOHCA patients (survival to discharge, 3.7% vs 6.2%, p<0.001; good neurological outcomes, 1.3% vs 3.2%, p<0.001). There were no significant differences between pOHCA and non-pOHCA patients in terms of the adjusted ORs for survival to discharge (adjusted OR 0.608; 95% CI 0.86 to 1.27) and good neurological outcomes (adjusted OR 1.03; 95% CI 0.73 to 1.42).ConclusionThis study shows that apparent aetiology of OHCA caused by poison, did not influence survival to discharge and good neurological outcomes. Furthermore, pOHCA occurs in younger patients and has fewer witnesses and shockable rhythms. pOHCA did not influence survival to discharge and good neurological outcomes. Also, pesticides and gases were the most frequent substances causing pOHCA in South Korea.

APA, Harvard, Vancouver, ISO, and other styles

44

Prabkaran, S., and K. Kasthuri Thilagam. "Survival outcomes of trachea esophageal fistula in infant." International Journal of Contemporary Pediatrics 6, no. 4 (June 27, 2019): 1680. http://dx.doi.org/10.18203/2349-3291.ijcp20192776.

Full text

Abstract:

Background: Tracheo-esophageal fistula (TEF) is a rare congenital abnormality often associated with several other anomalies including renal, vertebral column, gastrointestinal or cardiovascular defects. This study was carried out to evaluate the outcome of trachea esophageal fistula among patients who underwent various surgeries for the anastomosis of trachea esophageal fistula.Methods: This study was conducted as a record based cross sectional study among 88 patients who were diagnosed and treated for trachea-esophageal fistula in tertiary care hospital between 2015 and 2018. Data regarding the type of anomaly, presence of associated anomalies, type of surgery and outcomes were documented. Findings of echocardiography and ultrasonography were also documented. Data was analyzed using SPSS software. Chi square test was used to evaluate the outcome of the surgical procedures for management of TEF.Results: Majority of the participants in our study belong to <1 month of age and were males (56.8%). Type 3 tracheo esophageal fistula (80.7%) was the most common type. Associated cardiovascular anomalies were present in 50% of the participants. Thoracotomy with TEF repair was most preferred surgery (76%). Present study demonstrated that surgical techniques improve the physical and physiological outcome of the patients (p <0.05).Conclusions: Trachea esophageal fistula needs to be corrected with surgical procedure. Modern techniques like thorocoscopic anastomosis, thorocosopic techniques to achieve an anastomosis can also be explored. Future studies may be directed in detecting congenital anomalies during the pre-natal period with the help of genetic techniques.

APA, Harvard, Vancouver, ISO, and other styles

45

Abdou, Yara, Ahmed Elkhanany, Kristopher Attwood, Wenyan Ji, Kazuaki Takabe, and Mateusz Opyrchal. "Primary and secondary breast angiosarcoma: single center report and a meta-analysis." Breast Cancer Research and Treatment 178, no. 3 (September 14, 2019): 523–33. http://dx.doi.org/10.1007/s10549-019-05432-4.

Full text

Abstract:

Abstract Background Primary and secondary breast angiosarcoma is a rare and aggressive malignancy with limited published literature. Optimal management is mostly based on expert opinion. Our study aims to describe a single institution experience with breast angiosarcoma and evaluate other publications on this topic to further clarify prognostic outcomes and treatment modalities in this disease. Methods Twenty two cases of breast angiosarcoma from Roswell Park Comprehensive Cancer Center were retrospectively analyzed. Additionally, a systemic review and meta-analysis was conducted to study the association between survival outcomes, overall survival (OS), and recurrence-free survival (RFS) in both primary (PAS) and secondary breast angiosarcoma (SAS). Results 9 PAS patients (41%) and 13 SAS patients (59%) were retrospectively analyzed. No significant differences were noted in tumor characteristics and survival outcomes between PAS and SAS. Treatment modality had no significant effects on survival outcomes although adjuvant chemotherapy demonstrated a trend towards improved RFS in high grade tumors. 380 PAS and 595 SAS patients were included in the outcome meta-analysis. Survival outcomes were significantly worse with high grade tumors and tumor size of > 5 cm. Adjuvant radiation therapy demonstrated significantly better RFS, while adjuvant chemotherapy had no effect on survival outcomes. Conclusion Tumor size and grade seem to be reliable predictors of survival in both PAS and SAS. Mastectomy does not seem to be adding any additional benefit to BCS. Adjuvant radiation therapy showed statistically significant RFS benefit, while adjuvant chemotherapy can be beneficial in high grade tumors.

APA, Harvard, Vancouver, ISO, and other styles

46

White, Richard, Shaakir Hasan, Moses Raj, Dulabh K. Monga, Gene Grant Finley, Alexander V. Kirichenko, James McCormick, and Rodney E. Wegner. "Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 538. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.538.

Full text

Abstract:

538 Background: Primary Adenocarcinoma of the rectum is a rare disease with a poor prognosis and thus tends to have a more aggressive treatment algorithm, typically involving a surgical approach. Prior to 2001, a few retrospective studies outlined improved outcomes with the incorporation of surgery with chemoradiation. However, since the publication of these studies, advancement in radiotherapy modalities and imaging have left the question of improved outcomes while reserving surgery for salvage. We conducted this NCDB-driven, retrospective study to analyze treatment trends and outcomes in the current time from 2004-2015 with respect to chemoradiation and surgery. Methods: We queried the NCDB for with AJCC stage 1-3 anal adenocarcinoma diagnosed between 2004-2015. Propensity score-matched multivariable cox regression analysis determined the association of incorporation of surgery into the definitive management of anal adenocarcinoma on survival. Results: Of the 1729 patients eligible patients in this study, 1028 were treated with surgery as up front management and 701 had definitive chemoradiation. Median overall survival for all patients was 55 months with a 5 year survival rate of 55%. Patients treated without surgery had worse overall survival, median survival of 45 months compared to 87 months (p < .0001) with 5 year survivals of 42% and 55% in favor of incorporation of surgery. Analysis across patients treated with surgery alone, surgery followed by adjuvant chemoradiation, neoadjuvant chemoradiation followed by surgery, and chemoradiation alone had median survival rates of 78, 83, 92, and 46 months, respectively (p < 0.0001). Propensity score adjusted multivariable analysis identified older age, grade 3, high comorbidity score, and lack of surgery as predictive of worse outcome. Conclusions: The results of the NCDB analysis indicate improved overall survival with the incorporation of surgery into the initial management of anal adenocarcinoma when compared to chemoradiation alone, despite the omission of surgery in up to 50% of the cases logged. Our results corroborate earlier studies published prior for surgery to be included in the definitive management of anal adenocarcinoma.

APA, Harvard, Vancouver, ISO, and other styles

47

Perkins, Gavin D., Chen Ji, Felix Achana, John JM Black, Karl Charlton, James Crawford, Adam de Paeztron, et al. "Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT." Health Technology Assessment 25, no. 25 (April 2021): 1–166. http://dx.doi.org/10.3310/hta25250.

Full text

Abstract:

Background Adrenaline has been used as a treatment for cardiac arrest for many years, despite uncertainty about its effects on long-term outcomes and concerns that it may cause worse neurological outcomes. Objectives The objectives were to evaluate the effects of adrenaline on survival and neurological outcomes, and to assess the cost-effectiveness of adrenaline use. Design This was a pragmatic, randomised, allocation-concealed, placebo-controlled, parallel-group superiority trial and economic evaluation. Costs are expressed in Great British pounds and reported in 2016/17 prices. Setting This trial was set in five NHS ambulance services in England and Wales. Participants Adults treated for an out-of-hospital cardiac arrest were included. Patients were ineligible if they were pregnant, if they were aged < 16 years, if the cardiac arrest had been caused by anaphylaxis or life-threatening asthma, or if adrenaline had already been given. Interventions Participants were randomised to either adrenaline (1 mg) or placebo in a 1 : 1 allocation ratio by the opening of allocation-concealed treatment packs. Main outcome measures The primary outcome was survival to 30 days. The secondary outcomes were survival to hospital admission, survival to hospital discharge, survival at 3, 6 and 12 months, neurological outcomes and health-related quality of life through to 6 months. The economic evaluation assessed the incremental cost per quality-adjusted life-year gained from the perspective of the NHS and Personal Social Services. Participants, clinical teams and those assessing patient outcomes were masked to the treatment allocation. Results From December 2014 to October 2017, 8014 participants were assigned to the adrenaline (n = 4015) or to the placebo (n = 3999) arm. At 30 days, 130 out of 4012 participants (3.2%) in the adrenaline arm and 94 out of 3995 (2.4%) in the placebo arm were alive (adjusted odds ratio for survival 1.47, 95% confidence interval 1.09 to 1.97). For secondary outcomes, survival to hospital admission was higher for those receiving adrenaline than for those receiving placebo (23.6% vs. 8.0%; adjusted odds ratio 3.83, 95% confidence interval 3.30 to 4.43). The rate of favourable neurological outcome at hospital discharge was not significantly different between the arms (2.2% vs. 1.9%; adjusted odds ratio 1.19, 95% confidence interval 0.85 to 1.68). The pattern of improved survival but no significant improvement in neurological outcomes continued through to 6 months. By 12 months, survival in the adrenaline arm was 2.7%, compared with 2.0% in the placebo arm (adjusted odds ratio 1.38, 95% confidence interval 1.00 to 1.92). An adjusted subgroup analysis did not identify significant interactions. The incremental cost-effectiveness ratio for adrenaline was estimated at £1,693,003 per quality-adjusted life-year gained over the first 6 months after the cardiac arrest event and £81,070 per quality-adjusted life-year gained over the lifetime of survivors. Additional economic analyses estimated incremental cost-effectiveness ratios for adrenaline at £982,880 per percentage point increase in overall survival and £377,232 per percentage point increase in neurological outcomes over the first 6 months after the cardiac arrest. Limitations The estimate for survival with a favourable neurological outcome is imprecise because of the small numbers of patients surviving with a good outcome. Conclusions Adrenaline improved long-term survival, but there was no evidence that it significantly improved neurological outcomes. The incremental cost-effectiveness ratio per quality-adjusted life-year exceeds the threshold of £20,000–30,000 per quality-adjusted life-year usually supported by the NHS. Future work Further research is required to better understand patients’ preferences in relation to survival and neurological outcomes after out-of-hospital cardiac arrest and to aid interpretation of the trial findings from a patient and public perspective. Trial registration Current Controlled Trials ISRCTN73485024 and EudraCT 2014-000792-11. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 25. See the NIHR Journals Library website for further project information.

APA, Harvard, Vancouver, ISO, and other styles

48

Lagman, Carlito, Daniel T. Nagasawa, Daniel Azzam, John P. Sheppard, Cheng Hao Jacky Chen, Vera Ong, Thien Nguyen, et al. "Survival Outcomes After Intracranial Hemorrhage in Liver Disease." Operative Neurosurgery 16, no. 2 (May 15, 2018): 138–46. http://dx.doi.org/10.1093/ons/opy096.

Full text

Abstract:

Abstract BACKGROUND Survival outcomes for patients with liver disease who suffer an intracranial hemorrhage (ICH) have not been thoroughly investigated. OBJECTIVE To understand survival outcomes for 3 groups: (1) patients with an admission diagnosis of liver disease (end-stage liver disease [ESLD] or non-ESLD) who developed an ICH in the hospital, (2) patients with ESLD who undergo either operative vs nonoperative management, and (3) patients with ESLD on the liver transplant waitlist who developed an ICH in the hospital. METHODS We retrospectively reviewed hospital charts from March 2006 through February 2017 of patients with liver disease and an ICH evaluated by the neurosurgery service at a single academic medical center. The primary outcome was survival. RESULTS We included a total of 53 patients in this study. The overall survival for patients with an admission diagnosis of liver disease who developed an ICH (n = 29, 55%) in the hospital was 22%. Of those patients with an admission diagnosis of liver disease, 27 patients also had ESLD. Kaplan–Meier analysis found no significant difference in survival for ESLD patients (n = 33, 62%) according to operative status. There were 11 ESLD patients on the liver transplant waitlist. The overall survival for patients with ESLD on the liver transplant waitlist who suffered an in-hospital ICH (n = 7, 13%) was 14%. CONCLUSION ICH in the setting of liver disease carries a grave prognosis. Also, a survival advantage for surgical hematoma evacuation in ESLD patients is not clear.

APA, Harvard, Vancouver, ISO, and other styles

49

Lekawale, Hemant S., and Rachana V. Gaidole. "Outcomes of surgery in epithelial ovarian cancer: our experience." International Surgery Journal 6, no. 11 (October 24, 2019): 3906. http://dx.doi.org/10.18203/2349-2902.isj20194576.

Full text

Abstract:

Background: Comprehensive surgical staging and surgical cytoreduction is the primary modality of treatment in early and advanced epithelial ovarian cancer respectively, followed by systemic chemotherapy in most of the patients. The aim of the present study was to evaluate the role of surgery and its impact on disease free and overall survival in patients with epithelial ovarian cancer.Methods: A retrospective analysis of 38 patients of biopsy proven epithelial ovarian cancer was performed. Patient’s demographic data, details of surgical procedure, post-operative complications, histopathological findings, staging and pattern of recurrence were collected from the medical records.Results: Six (15.8%) patients had early disease (stage I-II) at presentation while 30 (94.7%) patients advanced disease (stage III-IV). Staging laparotomy was done in six (15.8%) patients, primary cytoreduction in eight (21.05%) patients, interval cytoreduction in 17 (81.6%) patients and secondary cytoreduction in two (5.3%) patients. Five (13.2%) patients were inoperable. The median follow up time was in the range of 2 to 56 months (median 26 months). The three years overall survival in advanced stage was 73.74%. Disease free survivals in primary and interval cytoreduction groups were 80% and 58.67% respectively. The disease free survival in patients with optimal cytoreduction was 72.9%.Conclusions: The present study indicates that in the majority of patients with advanced ovarian cancer, surgery can lead to optimal cytoreduction with acceptable disease-free and overall survival.

APA, Harvard, Vancouver, ISO, and other styles

50

Tran, T. N., M. Kashem, H. Zhao, G. Sunagawa, N. Shigemura, R. Yanagida, H. Kehara, and Y. Toyoda. "Survival Outcomes of Redo Lung Transplantation: UNOS Database." Journal of Heart and Lung Transplantation 40, no. 4 (April 2021): S367—S368. http://dx.doi.org/10.1016/j.healun.2021.01.1036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Survival outcomes'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles